Multiple Myeloma Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Sanofi, Karyopharm, AbbVie, Takeda, Celgene, Janssen, Pfizer, BioLineRx, ExCellThera, MorphoSys

 Breaking News
  • No posts were found

Multiple Myeloma Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Sanofi, Karyopharm, AbbVie, Takeda, Celgene, Janssen, Pfizer, BioLineRx, ExCellThera, MorphoSys

November 22
20:40 2023
Multiple Myeloma Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Sanofi, Karyopharm, AbbVie, Takeda, Celgene, Janssen, Pfizer, BioLineRx, ExCellThera, MorphoSys
Delveinsight Business Research LLP
The Multiple Myeloma market size in the 7MM was estimated to be nearly USD 20,000 million in 2022, which is expected to show positive growth by 2032. As per DelveInsight, the Multiple Myeloma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Multiple Myeloma and the launch of new therapies in the market.

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Myeloma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Multiple Myeloma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Multiple Myeloma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Multiple Myeloma: An Overview

According to the American Cancer Society, Multiple Myeloma (MM) is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system.

Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.

Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.

Multiple Myeloma Market Key Facts

  • The total market size for multiple myeloma in the United States was around USD 14,000 million in 2022, expected to rise by 2032.

  • Among the EU4 countries, Germany captured the maximum multiple myeloma market share in 2022, whereas Spain was at the bottom of the ladder in the same year.

  • In the first-line treatment-eligible group, Lenalidomide ± Bortezomib + dex captured the maximum market share, accounting for more than USD 1,000 million in 2022 in the 7MM and is expected to decline by 2032.

  • In the 4L+ setting, approved CAR-Ts (ABECMA and CARVYKTI) are expected to garner nearly USD 500 million in 2022 in the 7MM and will rise with the approval of other emerging CAR-Ts during the forecast period.

  • In the 7MM, the highest incident cases of multiple myeloma were seen in the United States, followed by EU4 and the UK.

  • Among EU4 countries, Germany accounted for the highest number of incident multiple myeloma cases, whereas Spain accounted for the lowest cases in 2022.

  • Multiple myeloma is more common in males as compared to females. More than 50% of males in the United States are diagnosed with multiple myeloma.

Multiple Myeloma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Multiple Myeloma pipeline therapies. It also thoroughly assesses the Multiple Myeloma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Multiple Myeloma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Multiple Myeloma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Multiple Myeloma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Multiple Myeloma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Multiple Myeloma Epidemiology, Segmented as –

  • Total Incident Cases of Multiple Myeloma in the 7MM [2019–2032]

  • Diagnosed cases of Multiple Myeloma by Age Distribution in the 7MM [2019–2032]

  • Total Symptomatic cases of Multiple Myeloma in the 7MM [2019–2032]

  • Cases of Multiple Myeloma by Treatment Line in the 7MM [2019–2032] 

  • Gender-specific cases of Multiple Myeloma in the 7MM [2019–2032]

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Multiple Myeloma market or expected to be launched during the study period. The analysis covers the Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Multiple Myeloma drugs based on their sale and market share.

The report also covers the Multiple Myeloma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Multiple Myeloma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Multiple Myeloma Market Will Evolve and Grow by 2032 @

Multiple Myeloma Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Multiple myeloma. Currently, Janssen Pharmaceuticals is leading the therapeutics market with its Multiple myeloma drug candidates in the most advanced stage of clinical development.

Multiple Myeloma Companies Actively Working in the Therapeutics Market Include

Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics) and Johnson & Johnson, MorphoSys AG/I-Mab Biopharma and others.

Emerging and Marketed Multiple Myeloma Therapies Covered in the Report Include:

  • Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio

  • Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline

  • Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech

  • Darzalex (Daratumumab): Janssen Biotech

  • Elranatamab: Pfizer

  • Felzartamab: Janssen Pharmaceutical

  • Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB

  • REGN5458: Regeneron Pharmaceuticals

  • Sarclisa (Isatuximab): Sanofi

  • Venetoclax (ABT-199): AbbVie and Roche

  • Xpovio (Selinexor): Karyopharm

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Multiple Myeloma Competitive Intelligence Analysis

4. Multiple Myeloma Market Overview at a Glance

5. Multiple Myeloma Disease Background and Overview

6. Multiple Myeloma Patient Journey

7. Multiple Myeloma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Multiple Myeloma Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Myeloma Unmet Needs

10. Key Endpoints of Multiple Myeloma Treatment

11. Multiple Myeloma Marketed Therapies

12. Multiple Myeloma Emerging Drugs and Latest Therapeutic Advances

13. Multiple Myeloma Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Myeloma Market Outlook (In US, EU5, and Japan)

16. Multiple Myeloma Companies Active in the Market

17. Multiple Myeloma Access and Reimbursement Overview

18. KOL Views on the Multiple Myeloma Market

19. Multiple Myeloma Market Drivers

20. Multiple Myeloma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hemorrhoids Market

“Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hemorrhoids market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hemorrhoids market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles